TRI-LUMA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-LUMA (TRI-LUMA).
Tri-Luma combines fluocinolone acetonide (corticosteroid), hydroquinone (melanocytotoxic agent), and tretinoin (retinoid). Fluocinolone reduces inflammation and melanocyte activity; hydroquinone inhibits tyrosinase, blocking melanin synthesis; tretinoin promotes epidermal turnover and enhances hydroquinone penetration.
| Metabolism | Fluocinolone acetonide is metabolized primarily in the liver via CYP3A4; hydroquinone undergoes conjugation (glucuronidation and sulfation) in the liver; tretinoin is metabolized by CYP450 enzymes (mainly CYP2C8, CYP2C9, and CYP3A4) and isomerized to isotretinoin. |
| Excretion | TRI-LUMA (fluocinolone acetonide, hydroquinone, tretinoin) is a topical combination; systemic absorption is minimal. The components are metabolized in the liver and excreted via urine (fluocinolone: ~70% renal, tretinoin: ~70% biliary/fecal, hydroquinone: ~80% renal as glucuronide conjugate). |
| Half-life | Fluocinolone acetonide: ~3.5 hours (topical); hydroquinone: ~4.8 hours (topical); tretinoin: ~1-2 hours (topical). Clinically, half-lives are short, allowing once-daily dosing. |
| Protein binding | Fluocinolone acetonide: ~90% bound to albumin and corticosteroid-binding globulin; hydroquinone: ~20% bound to albumin; tretinoin: >95% bound to albumin and lipoproteins. |
| Volume of Distribution | Due to minimal systemic absorption after topical application, Vd is not clinically meaningful; for reference, fluocinolone acetonide has a Vd of ~1.4 L/kg after IV administration. |
| Bioavailability | Topical: Systemic absorption is minimal (<5% for each component) due to low percutaneous penetration; not administered systemically. |
| Onset of Action | Topical: Effects on hyperpigmentation and acne may be noted within 2-4 weeks of consistent use. |
| Duration of Action | Topical: Duration of action is approximately 24 hours with once-daily application; clinical improvement is sustained with continued use. |
| Molecular Weight | Tretinoin 300.44 Da; Fluocinolone acetonide 452.49 Da; Hydroquinone 110.11 Da |
| Brand Substitutes | Lumaglo Forte Cream, Magnalyte Plus Cream, Lumacip Plus Cream |
Apply a thin layer to the face once daily at bedtime, covering the entire affected area.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustments are recommended; use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustments are recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended. |
| Geriatric use | Clinical studies have not included sufficient numbers; use with caution due to potential increased sensitivity. |
| 1st trimester | Contraindicated in pregnancy due to risk of fetal harm from tretinoin and fluorouracil. Fluorouracil is teratogenic; tretinoin is a retinoid with embryotoxic potential. |
| 2nd trimester | Contraindicated. Avoid use in second trimester due to systemic absorption of fluorouracil and tretinoin posing potential risks. |
| 3rd trimester | Contraindicated in third trimester. Systemic absorption could affect fetal development; avoid during labor and delivery. |
Clinical note
Comprehensive clinical and safety monograph for TRI-LUMA (TRI-LUMA).
| Placental transfer | Evidence suggests minimal placental transfer for topical application, but systemic absorption occurs. Fluorouracil crosses placenta; tretinoin may have low transfer but embryotoxic. Use contraindicated. |
| Breastfeeding | Caution should be exercised. Tretinoin and fluorouracil may be excreted in breast milk; potential for serious adverse reactions in nursing infants. Consider alternative therapy or discontinue nursing. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHypersensitivity to any componentSulfite sensitivity (hydroquinone contains sodium metabisulfite)
| Precautions | Skin irritation, depigmentation, exogenous ochronosis with prolonged hydroquinone use, photosensitivity, potential for skin atrophy and telangiectasias from corticosteroid, avoid use in patients with history of melanoma or other skin cancers, avoid sun exposure, use with caution in dark-skinned individuals due to risk of hypopigmentation. |
| Food/Dietary | No known food interactions. Avoid excessive sun exposure and photosensitizing foods (e.g., figs, celery, parsley) that may increase UV sensitivity. |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, topical corticosteroids have shown teratogenicity; however, the risk from topical application is lower than systemic. Tri-Luma contains hydroquinone, which has limited data; fluocinolone acetonide is a corticosteroid. First trimester: avoid due to theoretical risk. Second and third trimesters: use only if potential benefit justifies risk to fetus. |
| Fetal Monitoring | Monitor for maternal skin irritation, infection, or hypothalamic-pituitary-adrenal axis suppression with prolonged use. No specific fetal monitoring required unless topical corticosteroid used extensively on large areas, then consider monitoring for intrauterine growth restriction. |
| Fertility Effects | No known effects on fertility based on available data. Topical application minimizes systemic absorption, unlikely to impact reproductive function. |
| Clinical Pearls |
| Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) is a triple-combination cream for moderate-to-severe melasma. Use sun protection (SPF 30+) daily; limit treatment to 8 weeks due to risk of hydroquinone-induced ochronosis. Avoid application near eyes, mucous membranes, or broken skin. Monitor for skin atrophy and depigmentation. |
| Patient Advice | Apply a thin layer to affected areas only once daily at night, avoiding eyes, lips, and nostrils. · Wash hands after application and do not cover treated areas with bandages or makeup for at least 15 minutes. · Use a broad-spectrum sunscreen SPF 30+ and wear protective clothing daily to prevent melasma worsening. · Stop use and contact your doctor if you experience severe redness, blistering, or lightening of skin beyond treated areas. · Do not use longer than 8 weeks; a second course may be considered only after a skin-free period. · Avoid pregnancy or breastfeeding while using this medication; use effective contraception. |